Primary Mitochondrial Disease
Conditions
Keywords
Primary Mitochondrial Disease, Mitochondrial Myopathy, Elamipretide, MTP-131, Bendavia™
Brief summary
This randomized, double-blind, placebo-controlled, crossover study screened 32 subjects with primary mitochondrial myopathy (PMM) to evaluate the safety, tolerability, pharmacokinetics (PK), and efficacy of subcutaneous elamipretide in this patient population.
Detailed description
This randomized, double-blind, placebo-controlled, crossover study screened 32 subjects with primary mitochondrial myopathy (PMM) who had completed participation in the SPIMM-201 study where they had received 5 days of intravenous (IV) elamipretide (0.01, 0.10, or 0.25 mg/kg/hour infused for 2 hours) or placebo (randomized 3:1). The primary objective was to evaluate the effect of single daily subcutaneous (SC) doses of elamipretide administered for 4 weeks on the 6-minute walking distance (6MWD). Subjects were randomized (1:1) to one of two sequence groups: 4-weeks of treatment with 40 mg elamipretide administered once daily SC in Treatment Period 1 followed by 4-weeks of treatment with placebo administered once daily SC in Treatment Period 2 (separated by a 4-week washout period), or vice versa. Each sequence group went through 5 distinct periods: Screening, Treatment Period 1, Washout, Treatment Period 2, and Follow-Up. Safety, tolerability, pharmacokinetics (PK), and efficacy of subcutaneous elamipretide in this patient population were analyzed.
Interventions
DRUGElamipretide
4 weeks of treatment with 40 mg elamipretide administered once daily subcutaneously
DRUGPlacebo
4 weeks of treatment with placebo administered once daily subcutaneously
Sponsors
Stealth BioTherapeutics Inc.
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
16 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Subject completed participation in the SPIMM-201 study without a significant protocol deviation that would suggest the subject may not be able to complete all study requirements in the opinion of the Sponsor * Subject must reside in North America for the duration of the study * Subject has not received study drug in the SPIMM-201 study within 3 weeks prior to Screening * Women of childbearing potential must agree to use 1 of the methods of birth control specified in the protocol from the date they sign the informed consent form (ICF) until two months after the last dose of study drug * Subject has been on stable (unchanged and constant) medications (including over-the counter treatments, vitamins, or supplements) for at least 1 month prior to the Baseline Visit
Exclusion criteria
* Subject has any prior or current medical condition that, in the judgment of the Investigator, would prevent the subject from safely participating in and/or completing all study requirements (i.e. unstable angina or recent myocardial infarction) * Subject has received any investigational compound and/or has participated in another interventional clinical study within 30 days prior to the Baseline Visit or is concurrently enrolled in any non-interventional research of any type judged to be scientifically or medically incompatible with the study as deemed by the Investigator in consultation with the Sponsor * Subject experienced an adverse reaction to study drug in the SPIMM-201 study that contraindicates further treatment with elamipretide in the opinion of the Investigator and/or Sponsor * Female subjects who are pregnant, planning to become pregnant, or lactating * Subject has undergone an in-patient hospitalization within the 1 month prior to the Screening Visit or is likely to need in-patient hospitalization or a surgical procedure during the course of the study * Subject has a creatinine clearance ≤30 mL/min as calculated by the Cockcroft Gault equation * Subject has a corrected QT interval (QTc) elongation defined as a QTc \>450 msec in male subjects and \>480msec in female subjects. Note: At the initial electrocardiogram (ECG), if QTc exceeds these parameters, the ECG may be repeated 2 more times, and the average of the 3 QTc values used to determine the subjects eligibility * Subject has uncontrolled hypertension in the judgment of the Investigator (e.g. elevated above \>160 mmHg systolic or \>100 mmHg diastolic despite appropriate treatment on two consecutive readings) * Subject has a history of clinically significant hypersensitivity or allergy to any of the excipients contained in the study drug * Subject has a history of active alcoholism or drug addiction during the year before the Screening Visit
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Distance Walked on the 6-minute Walk Test (6MWT) by Visit | End of Week 4 and End of Week 12 | Distance in meters walked on the 6-minute walk test (6MWT) at end of treatment, where end of treatment means end of week 4 for Period 1 and end of week 12 for Period 2. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Wrist Accelerometer Counts by Day | Last 7 days prior to the date of end of treatment visit | Wrist Accelerometer Counts by the last 7 days prior to the date of the end of treatment visit; End of treatment being end of Week 4 for Treatment Period 1 and end of Week 12 for Treatment Period 2. Subjects wore an activity monitor, or wrist accelerometer, on their wrist daily (from the Screening Visit to the End-of-Study/Early Discontinuation Visit). As a measure of physical activity and mobility, subjects wore an activity monitor, or wrist accelerometer, which measured mean vector magnitude of accelerations per daywith higher counts indicating a more active status. Raw acceleration data was converted into proprietary counts which was used to estimate physical activity. The data was transformed from 30 Hz data into 1 minute epoch data; this 1 minute epoch data were used for the analysis of as the vector magnitude of the wrist data. |
| Average Hip Accelerator Counts by Day | Last 7 days prior to the date of end of treatment visit | Average Hip Accelerator Counts by last 7 days predose, and prior to end of treatment; End of treatment being Week 4 for Treatment Period 1 and Week 12 for Treatment Period 2. As a measure of physical activity and mobility, subjects wore an activity monitor, or hip accelerometer, on their hip (or belt line) daily during waking hours (minimum of at least 7 consecutive days immediately prior to study drug administration in each Treatment Period \[Predose; at Visit 2 for Treatment Period 1 and at Visit 4 for Treatment Period 2\]), and at the end of each Treatment Period \[at Visit 3 for Treatment Period 1 and Visit 5 for Treatment Period 2\]), which measured average acceleration per day, with higher counts indicating a more active status. Raw acceleration data was converted into proprietary counts which was used to estimate physical activity. The data was transformed from 30 Hz data into 1 minute epoch data; this 1 minute epoch data was used for the analysis of mean vertical axis (Y) cou |
| Neuro-QoL Fatigue Short Form Score: Total T-Scores (Question 1-8) | End of Week 4 and End of Week 12 | Participants respond to the following statements of the Quality of Life in Neurological Disorders Fatigue Assessment (Neuro-QOL Fatigue Item Bank at end of treatment: I felt exhausted;I felt that I had no energy; I felt fatigued; I was too tired to do my household chores;I was too tired to leave the house;I was frustrated by being too tired to do the things I wanted to do; I felt tired; I had to limit my social activity because I was tired.Individual response options range from a score of 1 to 5, where 1=Never, 2=Rarely, 3=Sometimes, 4=Often, and 5=Always for end of treatment, where end of treatment period is end of week 4 for period 1, and end of week 12 for period 2. Raw scores are calculated as simple summed scores to an Item Response Theory Metric referred to as the T-score metric. Higher T-score means more fatigue, which means a worse outcome, with possible scores ranging from 29.5 to 74.1. Mean population T-score and standard deviation was reported. |
| Primary Mitochondrial Myopathy Symptom Assessment (PMMSA) Total Fatigue Score by Week | Last 7 days of Week 4 and Last 7 days of Week 12 | Primary Mitochondrial Myopathy Symptom Assessment (PMMSA) Total Fatigue score at end of treatment (sum of Q1 to Q4; tiredness/muscle weakness) is scored as follows: 1=Not at all, 2=Mild, 3=Moderate, and 4=Severe. Total score range is 4-16; lower score means less fatigue and better outcome, higher score means more fatigue and worse outcome. Participants rate the following: Tiredness at rest, Tiredness during activities, Muscle weakness at rest, Muscle weakness during activities, at the end of each treatment period, where end of treatment period is the weekly average of the last 7 days of week 4 for period 1 and the last 7 days of week 12 for period 2. |
| Triple Timed Up and Go (3TUG) Test by Visit | End of Week 4 and End of Week 12 | Participant performed 3TUG test after the 6MWT, and after at least 15 minutes rest prior to study drug administration in each Treatment Period (End of Week 4 for Period 1 and End of Week 12 for Period 2.) Participant was directed to stand up from chair, walk at normal pace to the line on the floor 3 meters away,turn, walk back to the chair at normal pace, sit down again; activity was timed, in seconds. Activity is repeated 3 times consecutively without rest and an average time is calculated. |
| Patient Global Assessment [PGA] Score by Visit, Continuous | End of Week 4 and End of Week 12 | Patient-reported current health status at end of treatment, where end of treatment means End of Week 4 for Period 1 and End of Week 12 for Period 2. PGA Scale is as follows: 1=Excellent, 2=Very good, 3=Good, 4=Fair, and 5=Poor. Higher score means worse health status, means worse outcome. |
| Patient Global Assessment by Visit, Categorical | End of Week 4 and End of Week 12 | Patient-reported current health status at end of treatment, where end of treatment means End of Week 4 for Period 1 and End of Week 12 for Period 2. PGA Scale is as follows: 1=Excellent, 2=Very good, 3=Good, 4=Fair, and 5=Poor. Higher score means worse health status, means worse outcome. Excellent means excellent health, means better outcome; poor means poor health, means worse outcome. |
| Physician Global Assessment (PhGA) By Visit, Continuous | End of Week 4 and End of Week 12 | Physician Global Assessment (PhGA) Physician-reported overall health status at end of treatment, where end of treatment means End of Week 4 for Period 1 and End of Week 12 for Period 2.: 1=Excellent, 2=Very good, 3=Good, 4=Fair, and 5=Poor. Higher scores equal worse outcome. |
| Physician Global Assessment (PhGA) By Visit, Categorical | End of Week 4 and End of Week 12 | Physician Global Assessment (PhGA) Physician-reported overall health status at end of treatment, where end of treatment means End of Week 4 for Period 1 and End of Week 12 for Period 2.: 1=Excellent, 2=Very good, 3=Good, 4=Fair, and 5=Poor. Higher scores equal worse outcome. Excellent means excellent health, means better outcome; poor means poor health, means worse outcome. |
Countries
United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Elamipretide, Then Placebo Participants first received 40 mg of elamipretide once daily subcutaneously for 4 weeks. After a washout period of 4 weeks, they then received placebo administered once daily subcutaneously for 4 weeks. | 14 |
| Placebo, Then Elamipretide Participants first received placebo once daily subcutaneously for 4 weeks. After a washout period of 4 weeks, they then received 40 mg of elamipretide once daily subcutaneously for 4 weeks. | 16 |
| Total | 30 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 |
|---|---|---|---|
| Second Intervention (4 Weeks) | Physician Decision | 0 | 1 |
Baseline characteristics
| Characteristic | Elamipretide, Then Placebo | Placebo, Then Elamipretide | Total |
|---|---|---|---|
| Age, Continuous | 41.5 years STANDARD_DEVIATION 16.67 | 48.6 years STANDARD_DEVIATION 9.68 | 45.3 years STANDARD_DEVIATION 13.63 |
| Body Mass Index | 22.8 kg/m^2 STANDARD_DEVIATION 5.19 | 25.3 kg/m^2 STANDARD_DEVIATION 5.46 | 24.1 kg/m^2 STANDARD_DEVIATION 5.39 |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Asian | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Black or African American | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) More than one race | 1 Participants | 0 Participants | 1 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) White | 13 Participants | 16 Participants | 29 Participants |
| Region of Enrollment United States | 14 participants | 16 participants | 30 participants |
| Sex: Female, Male Female | 10 Participants | 15 Participants | 25 Participants |
| Sex: Female, Male Male | 4 Participants | 1 Participants | 5 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | 0 / 30 | 0 / 30 |
| other Total, other adverse events | 30 / 30 | 15 / 30 |
| serious Total, serious adverse events | 0 / 30 | 0 / 30 |
Outcome results
Primary
Distance Walked on the 6-minute Walk Test (6MWT) by Visit
Distance in meters walked on the 6-minute walk test (6MWT) at end of treatment, where end of treatment means end of week 4 for Period 1 and end of week 12 for Period 2.
Time frame: End of Week 4 and End of Week 12
Population: All participants for whom the distance walked on the 6MWT was measured.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Elamipretide | Distance Walked on the 6-minute Walk Test (6MWT) by Visit | 394.1 meters | Standard Deviation 134.16 |
| Placebo | Distance Walked on the 6-minute Walk Test (6MWT) by Visit | 378.2 meters | Standard Deviation 125.1 |
Secondary
Average Hip Accelerator Counts by Day
Average Hip Accelerator Counts by last 7 days predose, and prior to end of treatment; End of treatment being Week 4 for Treatment Period 1 and Week 12 for Treatment Period 2. As a measure of physical activity and mobility, subjects wore an activity monitor, or hip accelerometer, on their hip (or belt line) daily during waking hours (minimum of at least 7 consecutive days immediately prior to study drug administration in each Treatment Period \[Predose; at Visit 2 for Treatment Period 1 and at Visit 4 for Treatment Period 2\]), and at the end of each Treatment Period \[at Visit 3 for Treatment Period 1 and Visit 5 for Treatment Period 2\]), which measured average acceleration per day, with higher counts indicating a more active status. Raw acceleration data was converted into proprietary counts which was used to estimate physical activity. The data was transformed from 30 Hz data into 1 minute epoch data; this 1 minute epoch data was used for the analysis of mean vertical axis (Y) cou
Time frame: Last 7 days prior to the date of end of treatment visit
Population: All participants for whom hip accelerometer counts by day was measured.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Elamipretide | Average Hip Accelerator Counts by Day | Predose | 384.2 counts by day | Standard Deviation 130.7 |
| Elamipretide | Average Hip Accelerator Counts by Day | End of Treatment | 150.6 counts by day | Standard Deviation 162.13 |
| Placebo | Average Hip Accelerator Counts by Day | Predose | 380.6 counts by day | Standard Deviation 126.43 |
| Placebo | Average Hip Accelerator Counts by Day | End of Treatment | 148.1 counts by day | Standard Deviation 115.04 |
Secondary
Neuro-QoL Fatigue Short Form Score: Total T-Scores (Question 1-8)
Participants respond to the following statements of the Quality of Life in Neurological Disorders Fatigue Assessment (Neuro-QOL Fatigue Item Bank at end of treatment: I felt exhausted;I felt that I had no energy; I felt fatigued; I was too tired to do my household chores;I was too tired to leave the house;I was frustrated by being too tired to do the things I wanted to do; I felt tired; I had to limit my social activity because I was tired.Individual response options range from a score of 1 to 5, where 1=Never, 2=Rarely, 3=Sometimes, 4=Often, and 5=Always for end of treatment, where end of treatment period is end of week 4 for period 1, and end of week 12 for period 2. Raw scores are calculated as simple summed scores to an Item Response Theory Metric referred to as the T-score metric. Higher T-score means more fatigue, which means a worse outcome, with possible scores ranging from 29.5 to 74.1. Mean population T-score and standard deviation was reported.
Time frame: End of Week 4 and End of Week 12
Population: All participants for whom Neuro-QoL Fatigue Short Form Score was measured.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Elamipretide | Neuro-QoL Fatigue Short Form Score: Total T-Scores (Question 1-8) | 50.9 T-score | Standard Deviation 7.69 |
| Placebo | Neuro-QoL Fatigue Short Form Score: Total T-Scores (Question 1-8) | 54.7 T-score | Standard Deviation 10.35 |
Secondary
Patient Global Assessment by Visit, Categorical
Patient-reported current health status at end of treatment, where end of treatment means End of Week 4 for Period 1 and End of Week 12 for Period 2. PGA Scale is as follows: 1=Excellent, 2=Very good, 3=Good, 4=Fair, and 5=Poor. Higher score means worse health status, means worse outcome. Excellent means excellent health, means better outcome; poor means poor health, means worse outcome.
Time frame: End of Week 4 and End of Week 12
Population: All participants for whom the Patient Global Assessment was measured.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Elamipretide | Patient Global Assessment by Visit, Categorical | Excellent | 1 Participants |
| Elamipretide | Patient Global Assessment by Visit, Categorical | Fair | 11 Participants |
| Elamipretide | Patient Global Assessment by Visit, Categorical | Good | 12 Participants |
| Elamipretide | Patient Global Assessment by Visit, Categorical | Poor | 3 Participants |
| Elamipretide | Patient Global Assessment by Visit, Categorical | Very Good | 2 Participants |
| Placebo | Patient Global Assessment by Visit, Categorical | Poor | 7 Participants |
| Placebo | Patient Global Assessment by Visit, Categorical | Very Good | 2 Participants |
| Placebo | Patient Global Assessment by Visit, Categorical | Excellent | 1 Participants |
| Placebo | Patient Global Assessment by Visit, Categorical | Good | 8 Participants |
| Placebo | Patient Global Assessment by Visit, Categorical | Fair | 12 Participants |
Secondary
Patient Global Assessment [PGA] Score by Visit, Continuous
Patient-reported current health status at end of treatment, where end of treatment means End of Week 4 for Period 1 and End of Week 12 for Period 2. PGA Scale is as follows: 1=Excellent, 2=Very good, 3=Good, 4=Fair, and 5=Poor. Higher score means worse health status, means worse outcome.
Time frame: End of Week 4 and End of Week 12
Population: All participants for whom the Patient Global Assessment was measured.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Elamipretide | Patient Global Assessment [PGA] Score by Visit, Continuous | 3.4 score on a scale | Standard Deviation 0.91 |
| Placebo | Patient Global Assessment [PGA] Score by Visit, Continuous | 3.7 score on a scale | Standard Deviation 1.01 |
Secondary
Physician Global Assessment (PhGA) By Visit, Categorical
Physician Global Assessment (PhGA) Physician-reported overall health status at end of treatment, where end of treatment means End of Week 4 for Period 1 and End of Week 12 for Period 2.: 1=Excellent, 2=Very good, 3=Good, 4=Fair, and 5=Poor. Higher scores equal worse outcome. Excellent means excellent health, means better outcome; poor means poor health, means worse outcome.
Time frame: End of Week 4 and End of Week 12
Population: All participants for whom the Physician Global Assessment was measured.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Elamipretide | Physician Global Assessment (PhGA) By Visit, Categorical | Poor | 2 Participants |
| Elamipretide | Physician Global Assessment (PhGA) By Visit, Categorical | Excellent | 0 Participants |
| Elamipretide | Physician Global Assessment (PhGA) By Visit, Categorical | Very Good | 6 Participants |
| Elamipretide | Physician Global Assessment (PhGA) By Visit, Categorical | Good | 17 Participants |
| Elamipretide | Physician Global Assessment (PhGA) By Visit, Categorical | Fair | 4 Participants |
| Placebo | Physician Global Assessment (PhGA) By Visit, Categorical | Fair | 10 Participants |
| Placebo | Physician Global Assessment (PhGA) By Visit, Categorical | Good | 13 Participants |
| Placebo | Physician Global Assessment (PhGA) By Visit, Categorical | Excellent | 0 Participants |
| Placebo | Physician Global Assessment (PhGA) By Visit, Categorical | Poor | 2 Participants |
| Placebo | Physician Global Assessment (PhGA) By Visit, Categorical | Very Good | 5 Participants |
Secondary
Physician Global Assessment (PhGA) By Visit, Continuous
Physician Global Assessment (PhGA) Physician-reported overall health status at end of treatment, where end of treatment means End of Week 4 for Period 1 and End of Week 12 for Period 2.: 1=Excellent, 2=Very good, 3=Good, 4=Fair, and 5=Poor. Higher scores equal worse outcome.
Time frame: End of Week 4 and End of Week 12
Population: All participants for whom the Physician Global Assessment was measured.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Elamipretide | Physician Global Assessment (PhGA) By Visit, Continuous | 3.1 score on a scale | Standard Deviation 0.8 |
| Placebo | Physician Global Assessment (PhGA) By Visit, Continuous | 3.3 score on a scale | Standard Deviation 0.84 |
Secondary
Primary Mitochondrial Myopathy Symptom Assessment (PMMSA) Total Fatigue Score by Week
Primary Mitochondrial Myopathy Symptom Assessment (PMMSA) Total Fatigue score at end of treatment (sum of Q1 to Q4; tiredness/muscle weakness) is scored as follows: 1=Not at all, 2=Mild, 3=Moderate, and 4=Severe. Total score range is 4-16; lower score means less fatigue and better outcome, higher score means more fatigue and worse outcome. Participants rate the following: Tiredness at rest, Tiredness during activities, Muscle weakness at rest, Muscle weakness during activities, at the end of each treatment period, where end of treatment period is the weekly average of the last 7 days of week 4 for period 1 and the last 7 days of week 12 for period 2.
Time frame: Last 7 days of Week 4 and Last 7 days of Week 12
Population: All participants for whom PMMSA was measured at end of treatment.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Elamipretide | Primary Mitochondrial Myopathy Symptom Assessment (PMMSA) Total Fatigue Score by Week | 9.1 score on a scale | Standard Deviation 2.35 |
| Placebo | Primary Mitochondrial Myopathy Symptom Assessment (PMMSA) Total Fatigue Score by Week | 10.7 score on a scale | Standard Deviation 2.88 |
Secondary
Triple Timed Up and Go (3TUG) Test by Visit
Participant performed 3TUG test after the 6MWT, and after at least 15 minutes rest prior to study drug administration in each Treatment Period (End of Week 4 for Period 1 and End of Week 12 for Period 2.) Participant was directed to stand up from chair, walk at normal pace to the line on the floor 3 meters away,turn, walk back to the chair at normal pace, sit down again; activity was timed, in seconds. Activity is repeated 3 times consecutively without rest and an average time is calculated.
Time frame: End of Week 4 and End of Week 12
Population: All participants for whom the 3TUG test was measured.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Elamipretide | Triple Timed Up and Go (3TUG) Test by Visit | 35.3 seconds | Standard Deviation 16.66 |
| Placebo | Triple Timed Up and Go (3TUG) Test by Visit | 35.2 seconds | Standard Deviation 15.79 |
Secondary
Wrist Accelerometer Counts by Day
Wrist Accelerometer Counts by the last 7 days prior to the date of the end of treatment visit; End of treatment being end of Week 4 for Treatment Period 1 and end of Week 12 for Treatment Period 2. Subjects wore an activity monitor, or wrist accelerometer, on their wrist daily (from the Screening Visit to the End-of-Study/Early Discontinuation Visit). As a measure of physical activity and mobility, subjects wore an activity monitor, or wrist accelerometer, which measured mean vector magnitude of accelerations per daywith higher counts indicating a more active status. Raw acceleration data was converted into proprietary counts which was used to estimate physical activity. The data was transformed from 30 Hz data into 1 minute epoch data; this 1 minute epoch data were used for the analysis of as the vector magnitude of the wrist data.
Time frame: Last 7 days prior to the date of end of treatment visit
Population: All participants for whom wrist accelerometer counts by day was measured.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Elamipretide | Wrist Accelerometer Counts by Day | 1329.4 counts by day | Standard Deviation 505.28 |
| Placebo | Wrist Accelerometer Counts by Day | 1286.3 counts by day | Standard Deviation 507.83 |